Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study

Table 2 Patients’ characteristics and dose of MSC injected

Variables	Mean (range)
Age/years	50 (34–63)
Gender (F/M)	7/6
KOA stage (II/III)	5/8
Cell dose in 1st treatment (10⁶)	30.8 (28–35)
Cell dose in 2nd treatment (10⁶)	30.4 (26–33)
Time interval/days between treatments	92.3 (90–110)

ISSN: 1749-799X